Paid articlePaywallWhy Biotech’s Rally Can Last This Time:
The stars align for a bull run in the sector
wsj.com/finance/stocks/why-biotechs-rally-can-last-this-time-b2845aa3
Story Details
| Last Updated | |
| Total Articles | 1 |
Main Topics
act of providing financial or material resources to support an activity, organization, or cause; encompasses public, private, and illicit sources of finance
Similar to This
Previous
Barron's Dec 08 25
Paid articlePaywall Kymera Therapeutics Stock Soars 30%. Why Investors Are Excited About Its Anti-Inflammatory Drug.
barrons.com/articles/kymera-therapeutics-stock-anti-inflammatory-drug-b511b373
Paid articlePaywall Turmoil at the FDA Threatens Biotech Recovery: Unexpected delays, infighting and a staffing crisis are fueling investor unease
wsj.com/health/pharma/turmoil-at-the-fda-threatens-biotech-recovery-b2be3e5b
on.wsj.com Nov 19 25
Paid articlePaywall Exclusive | AI Music Platform Suno Valued at $2.45 Billion: Startup has raised $250 million and says annual revenue has reached $200 million
wsj.com/business/media/ai-music-platform-suno-valued-at-2-45-billion-b6bda919
on.wsj.com Oct 29 25
Paid articlePaywall Exclusive | OpenAI’s Promise to Stay in California Helped Clear the Path for Its IPO
wsj.com/tech/ai/openais-promise-to-stay-in-california-helped-clear-the-path-for-its-ipo-3af1c31c
Paid articlePaywall Exclusive | Trump Allies Sold Sponsorships to What Appeared to Be a Treasury Event. It Wasn’t.
wsj.com/politics/policy/trump-allies-sold-sponsorships-to-what-appeared-to-be-a-treasury-event-it-wasnt-cb8445e0
on.wsj.com Oct 05 25
Paid articlePaywall Europe’s AI Startups Look Stateside for Bigger Checks, Quicker Deals: Founders seeking funding see U.S. investors as better fit for sector’s fast pace and huge ...
wsj.com/tech/ai/europes-ai-startups-look-stateside-for-bigger-checks-quicker-deals-1a1dff43
Paid articlePaywall Here’s why biotech UniQure’s stock just tripled, and brought ClearPoint shares up with it
marketwatch.com/story/heres-why-biotech-uniqures-stock-just-tripled-and-brought-clearpoint-shares-up-with-it-d10766d2
Paid articlePaywall Novartis to buy U.S. biotech in latest deal targeting firms in $1 billion to $3 billion range
marketwatch.com/story/novartis-to-buy-u-s-biotech-in-latest-deal-targeting-firms-in-1-billion-to-3-billion-range-4184f9f4
Paid articlePaywall Exclusive | How Hedge Funds Won Big on Obscure Drugmaker Abivax: Abivax surged almost 600% in one day, delivering big gains to some biotech-focused funds that ...
wsj.com/finance/investing/abivax-hedge-fund-investments-5e9bf955
on.wsj.com Aug 25 25
Paid articlePaywall Exclusive | Silicon Valley Launches Pro-AI PACs to Defend Industry in Midterm Elections
wsj.com/politics/silicon-valley-launches-pro-ai-pacs-to-defend-industry-in-midterm-elections-287905b3
Barron's Jul 30 25
Paid articlePaywall Biotech Has Been Stalling. 3 Stocks That Could See Healthy Gains.: The biotech sector is facing a pivotal moment, after a frustrating year of stalled rallies ...
barrons.com/articles/biotech-amgen-insmed-stock-7a17bf16
Paid articlePaywall Exclusive | AI Wildfire Detection Startup Raises $44 Million: Pano AI’s fundraising signals investor willingness to back startups that rely in part on government ...
wsj.com/articles/ai-wildfire-detection-startup-raises-44-million-2d662b00
Paid articlePaywall U.S. VCs Race to Tap China’s Biotech Innovation: Western drugmakers, investors increasingly aim to acquire Chinese compounds
wsj.com/articles/u-s-vcs-race-to-tap-chinas-biotech-innovation-836b3dd1
Paid articlePaywall Doctors Warn Accountants of Private-Equity Drain on Quality: You Could Be Next: Early opponents of corporate influence in healthcare see parallels in another ...
wsj.com/articles/doctors-warn-accountants-of-private-equity-drain-on-quality-you-could-be-next-1be0f0fd
Next